Banyan Biomarkers Inc.

For acute brain injury patients, the lack of any reliable biological markers makes it nearly impossible to design trials with any precision. Banyan Biomarkers believes it may hold the key to successful development of traumatic brain injury drugs with its diagnostic blood test-based biomarkers for calpain and caspese-enzymes released by dissolving dead and dying brain cells into the blood.